NASDAQ: KA - Kineta, Inc.

छह महीने के लिए लाभप्रदता: -18.63%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम Kineta, Inc.


कंपनी के बारे में

Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer.

अधिक जानकारी
It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.

EBITDA -0.0597
EV/EBITDA -1.78
IPO date 2016-02-11
ISIN US49461C1027
Industry Biotechnology
P/BV 1.89
P/S 23.63
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.005
Див.доход ао 0
Дивиденд ао 10.01
Сайт https://kinetabio.com
Цена ао 0.5521
Число акций ао 0.01105 млрд
प्रति दिन मूल्य परिवर्तन: 0% (0.4801)
प्रति सप्ताह मूल्य परिवर्तन: 0% (0.4801)
प्रति माह मूल्य परिवर्तन: 0% (0.4801)
3 महीने में कीमत में बदलाव: -14.27% (0.56)
छह महीने में कीमत में बदलाव: -18.63% (0.59)
प्रति वर्ष मूल्य परिवर्तन: -86.77% (3.63)
3 वर्षों में मूल्य परिवर्तन: -85.09% (3.22)
5 वर्षों में मूल्य परिवर्तन: -74.6% (1.89)
10 वर्षों में मूल्य परिवर्तन: 0% (0.4801)
वर्ष की शुरुआत से मूल्य परिवर्तन: 0% (0.4801)

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 8.12 1
P/BV 14.45 1
P/E 0 0
EV/EBITDA -2.52 0
कुल: 4

क्षमता

नाम अर्थ श्रेणी
ROA, % -137.14 0
ROE, % -487.85 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0.5 5
कुल: 2.35

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.0838 10
कुल: 10

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % 8.84 2
लाभप्रदता Ebitda, % -73.68 0
लाभप्रदता EPS, % -99.21 0
कुल: 0.4

संस्थानों आयतन शेयर करना, %
Armistice Capital, LLC 825792 7.53
Vanguard Group Inc 151380 1.38
FMR, LLC 123719 1.13
Geode Capital Management, LLC 50584 0.46
Northern Trust Corporation 36880 0.34
Stifel Financial Corporation 21853 0.2
Financial Advocates Investment Management 21744 0.2
Blackrock Inc. 19957 0.18
Renaissance Technologies, LLC 19044 0.17
ELEMENT POINTE ADVISORS, LLC 17696 0.16



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Mr. Craig W. Philips President & Secretary 541.67k 1961 (64 वर्ष)
Ms. Pauline Kenny Esq., J.D. Advisor 349.72k 1974 (51 वर्ष)
Mr. Keith A. Baker Chief Financial Officer 485.75k 1967 (58 साल)
Dr. Thierry Guillaudeux Ph.D. Chief Scientific Officer N/A 1968 (57 साल)
Mr. Gary Gentges Executive Vice President of Corporate Development

पता: United States, Seattle. WA, 219 Terry Ave. N - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://kinetabio.com